• Sundaresan Nandhini Pharmacognosy and Phytochemistry Division, Interdisciplinary Institute of Indian System of Medicine, SRM University, Kattankulathur- 603 203, Kancheepuram (DT), Tamil Nadu, India.
  • Kasthuri Bai Narayanan Pharmacognosy and Phytochemistry Division, Interdisciplinary Institute of Indian System of Medicine, SRM University, Kattankulathur- 603 203, Kancheepuram (DT), Tamil Nadu, India.
  • Kaliappan Ilango Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM University, Kattankulathur- 603 203, Kancheepuram (DT), Tamil Nadu, India.



 Valeriana is a well-known Indian traditional medicinal herb with sleep remedy. It has been used over the years to treat nervine and sedative in hysteria, epilepsy, and sedative in nervous anxiety. It has also been used as an aromatic stimulant and reported some distinctive indications, as well as its use for rheumatism, low-grade fevers, and aphrodisiac. It has been known to grow well in regions of Europe, parts of Asia and North America. This systematic review focuses on the ethnopharmacological uses of Valeriana, including recent advances on the phytochemical and pharmacological study of Valeriana officinalis. In addition, future developments and scenarios in the study of the plant have been proposed. Various literature and electronic databases such as PubMed, ScienceDirect, Springer, and Wiley were searched and data obtained. Other online academic libraries such as Google Scholar and ethnopharmacological literature were searched systematically for more information on the plant. In this paper, we have reviewed various research conducted on V. officinalis especially in areas of its ethnopharmacological use, phytochemicals, and pharmacology. This plant has been used medicinally for a minimum of 2000 years. It is used in the treatment of brain disorder and also used for the treatment of varied nervous disorders, antispasmodic, anthelmintic, diuretic, diaphoretic, and emmenagogue, and hysteria. More research is needed in the area of pharmacokinetics and toxicology to give further information on the clinical use and control the quality of the plant.

Keywords: Valeriana officinalis, Ethnomedicine, Phytochemistry, Neuroprotective.

Author Biography

Sundaresan Nandhini, Pharmacognosy and Phytochemistry Division, Interdisciplinary Institute of Indian System of Medicine, SRM University, Kattankulathur- 603 203, Kancheepuram (DT), Tamil Nadu, India.
Department of pharmacognosy


1. Grieve M. In: Leyel CF, editor. A Modern Herbal. London: Tiger Books International; 1976. p. 912.
2. Hobbs C. Valerian monograph. Herbal Gram 1989;21:19-34.
3. Benigni R, Capra C, Cattorini P. Piante Medicinali Chimica Farmacologia E Terapia. Vol. 1. Milano: Inverni & Della Beffa; 1971. p. 730.
4. King J. The American Dispensatory. 7th ed. Cincinnati: Moore, Wilstach & Baldwin; 1866. p. 1509.
5. Ellingwood F, Lloyd JU. A Systematic Treatise on Materia Medica and Therapeutics. Chicago: Chicago Med Press; 1900. p. 706.
6. Scudder JM. Specific Medications and Specific Medicines. 15th ed. Cincinnati: Scudder Bros; 1903, 1985. p. 432.
7. Arshad HR, Yousef HA. Potential role of Carica papaya and their active constituents in the prevention and treatment of diseases. Int J Pharm Pharm Sci 2016;8:11-5.
8. Fleming T. PDR for Herbal Medicines. Montvale, NJ: Medical Economics Company, Inc.; 1998.
9. Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med 2000;1:91-9.
10. Malva JO, Santos S, Macedo T. Neuroprotective properties of Valeriana officinalis extracts. Neurotox Res 2004;6:131-40.
11. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res 2004;18:831-6.
12. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999;51:505-12.
13. Council of Scientific and Industrial Research. Valeriana officinalis Linn. The Wealth of India: A Dictionary of Indian Materials and Industrial Products. Vol. 9. New Delhi: Council of Scientific and Industrial Research; 2009. p. 426.
14. Andrews MJ, Basu A. US Patent No. 6 913 770 B2; 2005.
15. Straube G. The importance of valerian roots in therapy. Ther Ggw 1968;107:555-62.
16. Valerian (Herb). Wikipedia, the Free Encyclopedia. Available from:
17. Valerian (Valeriana officinalis) Overview, Health Benefits, Side Effects. Available from:
18. Valeriana officinalis Encyclopedia on Indian Medicinal Plants. Available from:
19. Khare CP. Indian Medicinal Plants: An Illustrated Dictionary. New York: Springer; 2007. p. 692.
20. Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London: The Pharmaceutical Press; 1996.
21. Bissett NG. Herbal Drugs and Phytopharmaceuticals. Stuttgart: Med Pharm CRC Press; 1994. p. 566.
22. Marder M, Viola H, Wasowski C, Fernández S, Medina JH, Paladini AC 6-methylapigenin and hesperidin: New valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 2003;75:537-45.
23. Khom S, Baburin I, Timin E, Hohaus A, Trauner G, Kopp B, et al. Valerenic acid potentiates and inhibits GABA(A) receptors: Molecular mechanism and subunit specificity. Neuropharmacology 2007;53:178-87.
24. Benke D, Barberis A, Kopp S, Altmann KH, Schubiger M, Vogt KE, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009;56:174-81.
25. Goppel M, Franz G. Stability control of valerian ground material and extracts: A new HPLC-method for the routine quantification of valerenic acids and lignans. Pharmazie 2004;59:446-52.
26. Wang PC, Ran XH, Chen R, Luo HR, Liu YQ, Zhou J, et al. Germacrane-type sesquiterpenoids from the roots of Valeriana officinalis var. latifolia. J Nat Prod 2010;73:1563-7.
27. Chavadej S, Becker H, Weberling F. Further investigations of valepotriates in the Valerianaceae. Pharm Weekbl Sci 1985;7:167-8.
28. Wagner H, Schaette R, Hörhammer L, Hölzl J. Dependence of the valepotriate and essential oil content in Valeriana officinalis L.s.l. on various exogenous and endogenous factors. Arzneimittelforschung 1972;22:1204-9.
29. Wang PC, Ran XH, Luo HR, Hu JM, Chen R, Ma QY, et al. Volvalerelactones A and B, two new sesquiterpenoid lactones with an unprecedented skeleton from Valeriana officinalis var. Latifolia. Org Lett 2011;13:3036-9.
30. Chen HW, Chen L, Li B, Yin HL, Tian Y, Wang Q, et al. Three new
germacrane-type sesquiterpenes with NGF-potentiating activity from Valeriana officinalis var. Latiofolia. Molecules 2013;18:14138-47.
31. Han ZZ, Zu XP, Wang JX, Li HL, Chen BY, Liu QX, et al. Neomerane-type sesquiterpenoids from Valeriana officinalis var. Latifolia. Tetrahedron 2014;70:962-6.
32. Oshima Y, Matsuoka S, Ohizumi Y. Antidepressant principles of Valeriana fauriei roots. Chem Pharm Bull (Tokyo)1995;43:169-70.
33. Jia JN, Zhang BH. Effect of valerian extract (V3d) on cardiovascular system [J]. J Guangxi Coll Tradit Chin Med 1999;16:40-2.
34. Becker H, Chavadej S. Valepotriate production of normal and colchicine-treated cell suspension cultures of Valeriana wallichii. J Nat Prod 1985;48:17-21.
35. McCabe S. Complementary herbal and alternative drugs in clinical practice. Perspect Psychiatr Care 2002;38:98-107.
36. Nithya S, Sundaram MM. An overview on the biological perspectives of Nardostachys jatamansi. Int J Pharm Pharm Sci 2016;8:31-6.
37. Morazzoni P, Bombardelli E. Valeriana officinalis: Traditional use and recent evaluation of activity. Fitoterapia 1995;66:99-112.
38. Miguel H, Feistel B, Hartwig S, Romanus L, Mirjam H, Hilke W. Extracts of Valeriana officinalis L. S.L. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 2008;15:2-15.
39. Hazelhoff B, Malingré TM, Meijer DK. Antispasmodic effects of valeriana compounds: An in-vivo and in-vitro study on the guinea-pig ileum. Arch Int Pharmacodyn Ther 1982;257:274-87.
40. Murakami N, Ye Y, Kawanishi M, Aoki S, Kudo N, Yoshida M, et al. New rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002;12:2807-10.
41. Carlini EA. Plants and the central nervous system. Pharmacol Biochem Behav 2003;75:501-12.
42. Hendriks H, Bos R, Allersma DP, Malingré TM, Koster AS. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med 1981;42:62-8.
43. Wang PC, Ran XH, Luo HR, Ma QY, Zhou J, Hu JM, et al. Volvalerine A, an unprecedented N-containing sesquiterpenoid dimer derivative from Valeriana officinalis var. Latifolia. Fitoterapia 2016;109:174-8.
44. Mirzaei M, Dinpanah H. Three phases hollow fiber LPME combined with HPLC-UV for extraction, preconcentration and determination of valerenic acid in Valeriana officinalis. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1870-4.
45. Wang PC, Ran XH, Chen R, Li LC, Xiong SS, Liu YQ, et al. Volvalerenone a, a new type of mononorsesquiterpenoid with an unprecedented 3, 12-oxo bridge from Valeriana officinalis. Tetrahedron Lett 2010;51:5451-3.
46. Ying ZH, Ying FA, Zhan-Feng GO, Xue-Yun DU, Yan-Wen LI. Two new terpenoids from Valeriana officinalis. Chin J Nat Med 2009;7:270-3.
47. Wills RB, Shohet D. Changes in valerenic acids content of valerian root (Valeriana officinalis L. SL.) during long-term storage. Food Chem 2009;115:250-3.
48. Safaralie A, Fatemi S, Sefidkon F. Essential oil composition of Valeriana officinalis L. roots cultivated in Iran. Comparative analysis between supercritical CO2 extraction and hydrodistillation. J Chromatogr A 2008;1180:159-64.
49. Huang B, Qin L, Chu Q, Zhang Q, Gao L, Zheng H. Comparison of headspace SPME with hydrodistillation and SFE for analysis of the volatile components of the roots of Valeriana officinalis var. Latifolia. Chromatographia 2009;69:489.
50. Hromádková Z, Ebringerová A, Valachovic P. Ultrasound-assisted extraction of water-soluble polysaccharides from the roots of valerian (Valeriana officinalis L.). Ultrason Sonochem 2002;9:37-44.
51. Paul C, König WA, Muhle H. Pacifigorgianes and tamariscene as constituents of Frullania tamarisci and Valeriana officinalis. Phytochemistry 2001;57:307-13.
52. Tori M, Yoshida M, Yokoyama M, Asakawa Y. A guaiane-type sesquiterpene, valeracetate from Valeriana officinalis. Phytochemistry 1996;41:977-9.
53. Gränicher F, Christen P, Kapetanidis I. Essential oils from normal and hairy roots of Valeriana officinalis var. Sambucifolia. Phytochemistry 1995;40:1421-4.
54. Gränicher F, Christen P, Kamalaprija P, Burger U. An iridoiddiester from Valeriana officinalis var. Sambucifolia hairy roots. Phytochemistry 1995;38:103-5.
55. Lokar LC, Moneghini M. Geographical variation in the monoterpenes of Valeriana officinalis Leaf. Biochem Syst Ecol 1989;17:563-7.
56. Bos R, Hendriks H, Bruins AP, Kloosterman J, Sipma G. Isolation and identification of valerenane sesquiterpenoids from Valeriana officinalis. Phytochemistry 1985;25:133-5.
57. Bos R, Hendriks H, Kloosterman J, Sipma G. A structure of faurinone, a sesquiterpene ketone isolated from Valeriana officinalis. Phytochemistry 1983;22:1505-6.
58. Hendriks H, Geertsma HJ, Malingré TM. The occurrence of valeranone and crypto-fauronol in the essential oil of Valeriana officinalis L. SL collected in the northern part of the Netherlands. Pharm World Sci 1981;3:1316-20.
59. Hazelhoff B, Weert B, Denee R, Malingré TM. Isolation and analytical aspects of Valeriana compounds. Pharm World Sci 1979;1:956-64.
60. Hazelhoff B, Smith D, Malingré TM, Hendriks H. The essential oil of Valeriana officinalisL. SL. Pharm World Sci 1979;1:443-9.
61. Popov S, Handjieva N, Marekov N. A new valepotriate: 7-epi-deacetylisovaltrate from Valeriana officinalis. Phytochemistry 1974;13:2815-8.
62. Johnson RD, Waller GR. Isolation of actinidine from Valeriana officinalis. Phytochemistry 1971;10:3334-5.
63. Torssell R, Wahlberg K. The structure of the principal alkaloid from Valeriana officinalis (L.). Tetrahedron Lett 1966;7:445-8.
64. Chen HW, He XH, Yuan R, Wei BJ, Chen Z, Dong JX, et al. Sesquiterpenes and a monoterpenoid with acetylcholinesterase (AchE) inhibitory activity from Valeriana officinalis var. latiofolia in vitro and in vivo. Fitoterapia 2016;110:142-9.
65. Torres-Hernández BA, Del Valle-Mojica LM, Ortíz JG. Valerenic acid and Valeriana officinalis extracts delay onset of pentylenetetrazole (PTZ)-induced seizures in adult Danio rerio (Zebrafish). BMC Complement Altern Med 2015;15:228.
66. Nam SM, Choi JH, Yoo DY, Kim W, Jung HY, Kim JW, et al. Valeriana officinalis extract and its main component, valerenic acid, ameliorate D-galactose-induced reductions in memory, cell proliferation, and neuroblast differentiation by reducing corticosterone levels and lipid peroxidation. Exp Gerontol 2013;48:1369-77.
67. Shahidi S, Bathaei A, Pahlevani P. Antinociceptive effects of Valeriana extract in mice: Involvement of the dopaminergic and serotonergic systems. Neurophysiology 2013;45:448-52.
68. Sudati JH, Vieira FA, Pavin SS, Dias GR, Seeger RL, Golombieski R, et al. Valeriana officinalis attenuates the rotenone-induced toxicity in Drosophila melanogaster. Neurotoxicology 2013;37:118-26.
69. Pereira RP, Fachinetto R, de Souza Prestes A, Wagner C, Sudati JH, Boligon AA, et al. Valeriana officinalis ameliorates vacuous chewing movements induced by reserpine in rats. J Neural Transm (Vienna)2011;118:1547-57.
70. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: A phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol 2011;9:24-31.
71. Rezvani ME, Roohbakhsh A, Allahtavakoli M, Shamsizadeh A. Anticonvulsant effect of aqueous extract of Valeriana officinalis in amygdala-kindled rats: Possible involvement of adenosine. J Ethnopharmacol 2010;127:313-8.
72. Murphy K, Kubin ZJ, Shepherd JN, Ettinger RH. Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats. Phytomedicine 2010;17:674-8.
73. Sudati JH, Fachinetto R, Pereira RP, Boligon AA, Athayde ML, Soares FA, et al. In vitro antioxidant activity of Valeriana officinalis against different neurotoxic agents. Neurochem Res 2009;34:1372-9.
74. Fachinetto R, Villarinho JG, Wagner C, Pereira RP, Avila DS, Burger ME, et al. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: Role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1478-86.
75. de Oliveria DM, Barreto G, De Andrade DV, Saraceno E, Aon-Bertolino L, Capani F, et al. Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease. Neurochem Res 2009;34:215-20.
76. Do KH, Choi YW, Kim EK, Yun SJ, Kim MS, Lee SY, et al. Pinoresinol-4,4’-di-O-beta-D-glucoside from Valeriana officinalis root stimulates calcium mobilization and chemotactic migration of mouse embryo fibroblasts. Phytomedicine 2009;16:530-7.
77. Circosta C, De Pasquale R, Samperi S, Pino A, Occhiuto F. Biological and analytical characterization of two extracts from Valeriana officinalis. J Ethnopharmacol 2007;112:361-7.
670 Views | 1259 Downloads
How to Cite
Nandhini, S., K. B. Narayanan, and K. Ilango. “VALERIANA OFFICINALIS: A REVIEW OF ITS TRADITIONAL USES, PHYTOCHEMISTRY AND PHARMACOLOGY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 1, Jan. 2018, pp. 36-41, doi:10.22159/ajpcr.2018.v11i1.22588.
Review Article(s)